Background: Clinical follow-ups of patients that have recovered from severe acute respiratory syndrome (SARS) have demonstrated radiological, physical, and psychological abnormalities to varying degrees. It is important that follow-ups be carried out to assess the clinical significance and persistence of such abnormalities. Oseltamivir has been widely used to treat viral diseases in clinical settings. Objectives: The aim of this study was to describe the long-term outcomes of patients with SARS and to describe the effects of oseltamivir on SARS, along with variables associated with outcomes. Study design: This study evaluated 67 survivors of severe acute respiratory syndrome treated with or without oseltamivir for 12 years after discharge from the hospital. At each visit, patients underwent physical examinations, pulmonary-function testing, echocardiographic examinations, and quality-of-life evaluations. Results: All survivors were asymptomatic and had normal clinical examinations. Mild pulmonary abnormalities were detected by lung function tests in 7 (10.45%) subjects, including residual ground-glass opacification or fibrosis (n=6) and air trapping (n=1). The need for mechanical ventilation (P=0.02) during the illness was a significant risk factor in predicting pneumonic fibrosis. There were no significant cardio-pulmonary function differences between those survivors treated with or without oseltamivir. Median scores for the physical role domain of the 36-item Short-Form General Health Survey decreased more than scores in the normal population, along with no significant differences between the two groups. Conclusions: After a complete clinical resolution, a considerable proportion of patients affected with SARS recovered. There were no significant differences in cardio-pulmonary function and quality-of-life measures between those treated with or without oseltamivir.